Elto Pharma Receives
Notice of Allowance in Canada
for Patent Covering Use of Eltoprazine to
Treat non-ADHD Cognitive
Impairment
New York, NY --
May 1, 2018 -- InvestorsHub NewsWire -- Elto
Pharma, Inc., a specialty pharmaceutical, clinical-stage
wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc.
(OTCPK:
AMBS) advancing eltoprazine into a Phase 2b human clinical
trial for the treatment of the orphan indication Parkinson's
disease levodopa-induced dyskinesia (PD-LID), today announced that
the Canadian Intellectual Property Office recently issued a Notice
of Allowance for a patent application entitled "Use of Eltoprazine
for Improvement of Symptoms of Cognitive Impairment Associated with
non-ADHD Neurological and Mental Disorders" covering the use of
eltoprazine to treat a range of non-ADHD neurological and mental
conditions, including Parkinson's disease and Alzheimer's disease.
Upon issuance, the patent will extend exclusivity protection for
eltoprazine in Canada for the treatment of non-ADHD cognitive
impairment into 2029.
"Eltoprazine has a unique
pharmacodynamic profile and holds promise in exploring its effect
on cognitive impairment in a variety of neurological and
neuropsychiatric conditions. It has shown statistically significant
improvement of cognition in a proof of
concept study of adult patients with ADHD.
This suggests that it may have benefits for cognition in other
neuropsychiatric disorders that can be evaluated in clinical
trials" said Dr. Paula Trzepacz, Elto Pharma's Chief Medical
Advisor. "As we build the clinical data package around eltoprazine
in our Phase 2b PD-LID program, we will consider including
secondary endpoints that assess relevant aspects of
cognition."
About Elto Pharma,
Inc.
Elto Pharma, Inc. is
developing eltoprazine, an oral small molecule 5HT1A/1B partial
agonist in clinical development for the treatment of Parkinson's
disease levodopa-induced dyskinesia (PD-LID), aggression in
Alzheimer's disease and adult attention deficit hyperactivity
disorder (adult ADHD). Eltoprazine has been evaluated in over 680
human subjects to date, was well-tolerated and showed promising
efficacy results in both cognitive and movement disorders.
Eltoprazine has received orphan drug designation (ODD) from the US
FDA for the treatment of PD-LID.
Eltoprazine was originally
developed by Solvay (now Abbvie) for aggression-related
indications. The eltoprazine program was out-licensed to
PsychoGenics, Inc. (PGI). PGI licensed eltoprazine to Amarantus in
2014 after a successful proof-of-concept trial in
PD-LID.
In April 2017, Amarantus
incorporated the wholly-owned subsidiary Elto Pharma, Inc. for the
purpose of raising capital to finance the further clinical
development of eltoprazine.
About Amarantus
Bioscience Holdings, Inc.
Amarantus Bioscience
Holdings (AMBS), a JLABS alumnus company, is a biotechnology
company developing treatments and diagnostics for diseases in the
areas of neurology, regenerative medicine and orphan diseases
through its subsidiaries. AMBS' wholly-owned subsidiary Elto
Pharma, Inc. has development rights to eltoprazine, a Phase
2b-ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, Alzheimer's aggression and adult
attention deficit hyperactivity disorder, commonly known as ADHD.
AMBS acquired the rights to the Engineered Skin Substitute program,
a regenerative medicine-based approach for treating severe burns
with full-thickness autologous skin grown in tissue culture that is
being pursued by AMBS' wholly-owned subsidiary Cutanogen
Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics,
Inc. owns key intellectual property rights and licenses from a
number of prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor ("MANF"). MANF Therapeutics, Inc.
is developing MANF-based products as treatments for brain and
ophthalmic disorders. MANF was discovered by the Company's Chief
Scientific Officer John Commissiong, PhD. Dr. Commissiong
discovered MANF from AMBS' proprietary discovery engine PhenoGuard.
The Company also re-acquired rights to the Alzheimer's blood
diagnostic LymPro Test , MSPrecise and NuroPro.
For further information
please visit www.Amarantus.com, or connect with the Amarantus on Facebook,LinkedIn,Twitterand Google+.
Amarantus
Investor and Media Contact:
Howard
Gostfrand
American Capital Ventures,
Inc.
Office:
305-918-7000
Email: hg@amcapventures.com
Source: Amarantus
Bioscience Holdings, Inc.